Published in Analyst on January 01, 2003
Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia. PLoS Med (2006) 2.95
Metabolomics-based methods for early disease diagnostics. Expert Rev Mol Diagn (2008) 2.51
The emerging field of quantitative blood metabolomics for biomarker discovery in critical illnesses. Am J Respir Crit Care Med (2011) 2.02
Biomarkers of inflammation, immunosuppression and stress with active disease are revealed by metabolomic profiling of tuberculosis patients. PLoS One (2012) 1.97
The Cinderella story of metabolic profiling: does metabolomics get to go to the functional genomics ball? Philos Trans R Soc Lond B Biol Sci (2006) 1.63
Metabolomics as a tool for cardiac research. Nat Rev Cardiol (2011) 1.51
Early stage diagnosis of oral cancer using 1H NMR-based metabolomics. Neoplasia (2009) 1.50
Metabolomic analysis and signatures in motor neuron disease. Metabolomics (2005) 1.31
Novel biomarkers for predicting preeclampsia. Trends Cardiovasc Med (2008) 1.20
Metabolic profiling of Parkinson's disease: evidence of biomarker from gene expression analysis and rapid neural network detection. J Biomed Sci (2009) 1.03
Metabolomics of neural progenitor cells: a novel approach to biomarker discovery. Cold Spring Harb Symp Quant Biol (2008) 1.02
Prehypertension-associated elevation in circulating lysophosphatidlycholines, Lp-PLA2 activity, and oxidative stress. PLoS One (2014) 0.87
Gut microbiota dysbiosis contributes to the development of hypertension. Microbiome (2017) 0.87
Interrogating causal pathways linking genetic variants, small molecule metabolites, and circulating lipids. Genome Med (2014) 0.86
Metabolomic analyses for atherosclerosis, diabetes, and obesity. Biomark Res (2013) 0.83
Metabolic profiling of patients with schizophrenia. PLoS Med (2006) 0.82
The Effect of LC-MS Data Preprocessing Methods on the Selection of Plasma Biomarkers in Fed vs. Fasted Rats. Metabolites (2012) 0.81
Analysis of serum metabolic profile by ultra-performance liquid chromatography-mass spectrometry for biomarkers discovery: application in a pilot study to discriminate patients with tuberculosis. Chin Med J (Engl) (2015) 0.78
Reconstruction and analysis of correlation networks based on GC-MS metabolomics data for young hypertensive men. Anal Chim Acta (2014) 0.77
Differential regulations of blood pressure and perturbed metabolism by total ginsenosides and conventional antihypertensive agents in spontaneously hypertensive rats. Acta Pharmacol Sin (2010) 0.76
A metabonomic analysis of serum from rats treated with ricinine using ultra performance liquid chromatography coupled with mass spectrometry. PLoS One (2014) 0.76
Metabolic differentiation and classification of abnormal Savda Munziq's pharmacodynamic role on rat models with different diseases by nuclear magnetic resonance-based metabonomics. Pharmacogn Mag (2015) 0.76
Background correction in near-infrared spectra of plant extracts by orthogonal signal correction. J Zhejiang Univ Sci B (2005) 0.75
Quantitative analysis of urea in human urine and serum by 1H nuclear magnetic resonance. Analyst (2011) 0.75
(1)H NMR-Based Analysis of Serum Metabolites in Monocrotaline-Induced Pulmonary Arterial Hypertensive Rats. Dis Markers (2016) 0.75
Concentration profiling in rat tissue by high-resolution magic-angle spinning NMR spectroscopy: investigation of a model drug. Anal Chem (2005) 0.75
A Nested Case-Control Study of Association between Metabolome and Hypertension Risk. Biomed Res Int (2016) 0.75
A Targeted Metabolomics MRM-MS Study on Identifying Potential Hypertension Biomarkers in Human Plasma and Evaluating Acupuncture Effects. Sci Rep (2016) 0.75
Host-gut microbiota metabolic interactions. Science (2012) 7.73
Gut microbiomes of Malawian twin pairs discordant for kwashiorkor. Science (2013) 6.98
Symbiotic gut microbes modulate human metabolic phenotypes. Proc Natl Acad Sci U S A (2008) 6.42
Metabonomics: a platform for studying drug toxicity and gene function. Nat Rev Drug Discov (2002) 5.96
Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat Protoc (2007) 5.92
Human metabolic phenotype diversity and its association with diet and blood pressure. Nature (2008) 5.41
Gut microorganisms, mammalian metabolism and personalized health care. Nat Rev Microbiol (2005) 5.35
Systems biology: Metabonomics. Nature (2008) 5.32
Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc Natl Acad Sci U S A (2006) 5.19
Cardiac Remote Ischemic Preconditioning in Coronary Stenting (CRISP Stent) Study: a prospective, randomized control trial. Circulation (2009) 4.61
Statistical total correlation spectroscopy: an exploratory approach for latent biomarker identification from metabolic 1H NMR data sets. Anal Chem (2005) 4.14
Chemometrics in metabonomics. J Proteome Res (2007) 4.02
Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics. Nat Med (2002) 3.91
A top-down systems biology view of microbiome-mammalian metabolic interactions in a mouse model. Mol Syst Biol (2007) 3.68
Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature (2006) 3.45
Metabolic surgery profoundly influences gut microbial-host metabolic cross-talk. Gut (2011) 3.42
Intraoperative tissue identification using rapid evaporative ionization mass spectrometry. Sci Transl Med (2013) 3.26
Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc Natl Acad Sci U S A (2009) 3.01
Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia. PLoS Med (2006) 2.95
Summary recommendations for standardization and reporting of metabolic analyses. Nat Biotechnol (2005) 2.90
Multiple parasite infections and their relationship to self-reported morbidity in a community of rural Côte d'Ivoire. Int J Epidemiol (2004) 2.84
Metabolic phenotyping in health and disease. Cell (2008) 2.80
Gut microbiota: a potential new territory for drug targeting. Nat Rev Drug Discov (2008) 2.59
Systemic gut microbial modulation of bile acid metabolism in host tissue compartments. Proc Natl Acad Sci U S A (2010) 2.52
Gut microbiome-host interactions in health and disease. Genome Med (2011) 2.48
Association between IVUS findings and adverse outcomes in patients with coronary artery disease: the VIVA (VH-IVUS in Vulnerable Atherosclerosis) Study. JACC Cardiovasc Imaging (2011) 2.43
Probiotic modulation of symbiotic gut microbial-host metabolic interactions in a humanized microbiome mouse model. Mol Syst Biol (2008) 2.43
An open label, single-centre, randomized trial of spinal cord stimulation vs. percutaneous myocardial laser revascularization in patients with refractory angina pectoris: the SPiRiT trial. Eur Heart J (2006) 2.39
Global metabolic profiling procedures for urine using UPLC-MS. Nat Protoc (2010) 2.18
Systemic multicompartmental effects of the gut microbiome on mouse metabolic phenotypes. Mol Syst Biol (2008) 2.17
UPLC/MS(E); a new approach for generating molecular fragment information for biomarker structure elucidation. Rapid Commun Mass Spectrom (2006) 2.17
NMR-based metabonomic approaches for evaluating physiological influences on biofluid composition. NMR Biomed (2005) 2.15
Metabonomic investigations in mice infected with Schistosoma mansoni: an approach for biomarker identification. Proc Natl Acad Sci U S A (2004) 2.11
Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS). J Proteome Res (2009) 2.10
Metabolic phenotyping in clinical and surgical environments. Nature (2012) 2.09
Colonization-induced host-gut microbial metabolic interaction. MBio (2011) 2.04
The challenges of modeling mammalian biocomplexity. Nat Biotechnol (2004) 2.03
Optimized preprocessing of ultra-performance liquid chromatography/mass spectrometry urinary metabolic profiles for improved information recovery. Anal Chem (2011) 2.02
Global systems biology, personalized medicine and molecular epidemiology. Mol Syst Biol (2006) 1.99
Rapid and noninvasive metabonomic characterization of inflammatory bowel disease. J Proteome Res (2007) 1.99
How has healthcare research performance been assessed?: a systematic review. J R Soc Med (2011) 1.97
Susceptibility of human metabolic phenotypes to dietary modulation. J Proteome Res (2006) 1.96
High resolution "ultra performance" liquid chromatography coupled to oa-TOF mass spectrometry as a tool for differential metabolic pathway profiling in functional genomic studies. J Proteome Res (2005) 1.93
Metabonomics in pharmaceutical R&D. FEBS J (2007) 1.93
Using chemometrics for navigating in the large data sets of genomics, proteomics, and metabonomics (gpm). Anal Bioanal Chem (2004) 1.88
The human gut microbiome: implications for future health care. Curr Gastroenterol Rep (2008) 1.84
Metabonomics in ulcerative colitis: diagnostics, biomarker identification, and insight into the pathophysiology. J Proteome Res (2010) 1.84
A genome-wide metabolic QTL analysis in Europeans implicates two loci shaped by recent positive selection. PLoS Genet (2011) 1.83
Scaling and normalization effects in NMR spectroscopic metabonomic data sets. Anal Chem (2006) 1.81
Metabonomics technologies and their applications in physiological monitoring, drug safety assessment and disease diagnosis. Biomarkers (2004) 1.79
Global metabolic responses of NMRI mice to an experimental Plasmodium berghei infection. J Proteome Res (2008) 1.78
NMR-based metabolic profiling and metabonomic approaches to problems in molecular toxicology. Chem Res Toxicol (2008) 1.77
Assessment of analytical reproducibility of 1H NMR spectroscopy based metabonomics for large-scale epidemiological research: the INTERMAP Study. Anal Chem (2006) 1.76
High-resolution magic-angle-spinning NMR spectroscopy for metabolic profiling of intact tissues. Nat Protoc (2010) 1.76
Melamine-induced renal toxicity is mediated by the gut microbiota. Sci Transl Med (2013) 1.75
Understanding the role of gut microbiome-host metabolic signal disruption in health and disease. Trends Microbiol (2011) 1.72
Metabonomic and microbiological analysis of the dynamic effect of vancomycin-induced gut microbiota modification in the mouse. J Proteome Res (2008) 1.67
Direct quantitative trait locus mapping of mammalian metabolic phenotypes in diabetic and normoglycemic rat models. Nat Genet (2007) 1.66
Spectroscopic and statistical techniques for information recovery in metabonomics and metabolomics. Annu Rev Anal Chem (Palo Alto Calif) (2008) 1.63
Statistical heterospectroscopy, an approach to the integrated analysis of NMR and UPLC-MS data sets: application in metabonomic toxicology studies. Anal Chem (2006) 1.61
Human metabolic profiles are stably controlled by genetic and environmental variation. Mol Syst Biol (2011) 1.60
Recursive segment-wise peak alignment of biological (1)h NMR spectra for improved metabolic biomarker recovery. Anal Chem (2009) 1.59
Rapid diagnosis and staging of colorectal cancer via high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy of intact tissue biopsies. Ann Surg (2014) 1.58
Top-down systems biology modeling of host metabotype-microbiome associations in obese rodents. J Proteome Res (2009) 1.57
Gut microbiota composition and activity in relation to host metabolic phenotype and disease risk. Cell Metab (2012) 1.55